Clinical Core

临床核心

• 批准号: 10647864
• 负责人: Victor Henderson
• 金额: $ 88.41万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10647864
• 关键词: Acceleration; Adherence; Adopted; Adult; Age; Aging; Agreement; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Amyloid; Amyloid beta-Protein; Behavior assessment; Behavioral; Biological Markers; Brain; Catchment Area; Categories; Clinical; Clinical Trials; Clinical assessments; Cognitive; Cognitive aging; Consensus; Consent; Data; Dementia; Dementia with Lewy Bodies; Development; Diagnosis; Disease; Elderly; Enrollment; Environment; Ethnic Population; Faculty; Family history of; First Degree Relative; Funding; Genetic; Goals; Grant; Hispanic; Image; Immune System Diseases; Impaired cognition; Individual; Latino; Lewy Bodies; Magnetic Resonance Imaging; Measures; Medical Research; Medical Students; Minority Enrollment; Nerve Degeneration; Neurodegenerative Disorders; Neurofibrillary Tangles; Neurologic; Parkinson Disease; Parkinson' s Dementia; Participant; Pathogenesis; Patients; Phenotype; Population; Population Control; Populations at Risk; Positron-Emission Tomography; Protocols documentation; Qualifying; Research; Research Personnel; Research Support; Resistance; Resources; Risk; Therapeutic; Time; Training; Work; alpha synuclein; amyloid imaging; cognitive testing; cohort; education research; follow-up; graduate student; insight; mild cognitive impairment; motor impairment; neuropathology; outreach; participant enrollment; participant retention; pre-clinical; protein misfolding; recruit; resilience; tau Proteins

1. SUMMARY (Clinical Core) In support of the goals of the National Alzheimer's Project Act, the Stanford ADRC will focus on the Alzheimer's disease (AD) spectrum and the Lewy body (LB) spectrum of neurodegenerative cognitive impairment. Recognizing that critical answers will emerge more readily when investigators can delve deeply within and across multiple levels of participant data, we have adopted a strategy of deep phenotyping. Stanford ADRC participants are characterized intensively and followed over time. The AD spectrum includes cognitively impaired patients with AD dementia and mild cognitive impairment due to AD, as well as preclinical AD inferred from biomarker data. The LB spectrum encompasses dementia with Lewy bodies and Parkinson's disease dementia and Parkinson's disease patients with mild cognitive impairment. Healthy adults without cognitive or motor impairment can serve as an age-equivalent comparison population, as an asymptomatic at-risk population, and as a potential preclinical population in which mechanisms of cognitive aging and preclinical transition can be studied. Within the LB spectrum, Parkinson's disease patients without cognitive impairment serve as age-equivalent comparators and as an at-risk transitional population for the development of LB- spectrum cognitive impairment. Stanford ADRC resources will enable the parallel study of these AD and LB spectrum disorders. Opportunities for investigators to compare and contrast can provide unique insights into pathogenesis, resistance and resilience, and therapeutic approaches. The Clinical Core will be responsible for participant enrollment and for clinical, cognitive, and behavioral assessments. In support of a strategy that emphasizes the deep phenotyping of individual participants, the Clinical Core is also responsible for biospecimen procurement, imaging referral, and brain donation consent. It is responsible for participant retention and for longitudinal follow-up. Most new participants in the Stanford ADRC will be asked to provide disease-defining biomarkers measured in CSF, imaged by amyloid-PET/MRI, or both; to consent to longitudinal follow-up; and to agree to brain donation through the Neuropathology Core. The Clinical Core will work with other ADRC Cores to accomplish four aims focused on the AD spectrum and the LB spectrum of neurodegenerative cognitive impairment: (1) Enroll participants into longitudinal research protocols of the Stanford ADRC; characterize their neurological, cognitive, and behavioral status; provide consensus diagnoses; follow participants longitudinally; and promote adherence; (2) support the efforts of other ADRC Cores; (3) support ADRC development project grants and research needs of qualified externally funded investigators who could benefit from Core resources; and (4) support the Research Education Component by providing a rich training environment for medical and graduate students, residents, fellows, and junior faculty.

1。摘要（临床核心） 为了支持《国家阿尔茨海默氏症计划法》的目标，斯坦福德ADRC将重点关注 阿尔茨海默氏病（AD）频谱和神经退行性认知的Lewy体（LB）谱 损害。当调查人员可以深入研究时，认识到关键答案将更容易出现 在多个参与者数据中，我们采用了深层表型的策略。斯坦福大学 ADRC参与者的特征是，随着时间的流逝。广告谱包括认知 AD痴呆症和轻度认知障碍的患者因AD而受损，以及临床前AD推断 来自生物标志物数据。 LB光谱涵盖了Lewy Bodies和Parkinson病的痴呆症 痴呆症和帕金森氏病轻度认知障碍的患者。没有认知或 运动障碍可以作为年龄相等的比较人群，作为无症状的处于危险中 人口，作为潜在的临床前种群，在这种临床前种群，认知老化和临床前的机制 可以研究过渡。在LB光谱中，帕金森氏病患者没有认知障碍 用作年龄等效的比较者，也是高危过渡人群的发展 频谱认知障碍。 Stanford ADRC资源将实现对这些广告和LB的平行研究 频谱障碍。调查人员比较和对比的机会可以为您提供独特的见解 发病机理，抗性和弹性以及治疗方法。临床核心将负责 参与者入学以及临床，认知和行为评估。支持一项策略 强调个人参与者的深层表型，临床核心也负责 生物循环采购，成像转介和大脑捐赠同意。它负责参与者 保留和纵向随访。斯坦福德ADRC的大多数新参与者将被要求提供 在CSF中测量的定义生物标志物，由淀粉样蛋白PET/MRI成像，或两者兼而有之；同意 纵向随访；并同意通过神经病理学核心进行大脑捐赠。临床核心将 与其他ADRC核心合作，以实现四个目标，重点是AD频谱和LB光谱 神经退行性认知障碍：（1）参与者参加纵向研究方案 斯坦福德ADRC；表征其神经，认知和行为状态；提供共识 诊断；纵向关注参与者；并促进依从性； （2）支持其他ADRC的努力 内核； （3）支持合格外部资助的ADRC开发项目赠款和研究需求 可以从核心资源中受益的调查人员； （4）支持研究教育部分 为医学和研究生，居民，研究员和初级教师提供丰富的培训环境。